News

Morphosys Reports Decreased Losses in Q2

1 Mins read

By Andrea Figueras

Morphosys, the German biopharmaceutical company, announced improved financial performance in the second quarter of the year. Despite a decline in revenue, lower costs helped narrow net and operating losses.

Strong Improvement in Financials

Morphosys reported a significant decrease in net loss for Q2, reducing it to 74 million euros ($81.2 million) compared to the previous year’s loss of EUR235 million. The company also saw a reduction in operating loss, with figures dropping from EUR55.1 million to EUR50.5 million.

Revenue Decline Offset by Cost Reductions

Although revenue dipped by 10% to EUR53.2 million, Morphosys successfully mitigated the impact through cost-cutting measures. The quarterly sales of Monjuvi, the company’s main product which treats lymphoma, remained stable at EUR21.7 million.

Positive Outlook for Monjuvi

Morphosys maintains a positive outlook for Monjuvi, anticipating net product sales in the U.S. to range between $80 million and $95 million for the year. The company expects a gross margin of 75% to 80% for Monjuvi and estimates research-and-development expenses to be between EUR290 million and EUR315 million.

Related posts
News

Unexpected Stock Market Rally

2 Mins read
Despite mixed expectations and original justifications falling apart, the stock market rally continues to soar, reaching new highs in various sectors. Let’s…
News

Analyst Sees Opportunity in DraftKings Stock

2 Mins read
A roughly 10% pullback in DraftKings Inc.’s stock following last week’s earnings report has caught the attention of analysts. Barclays’ Brandt Montour…
News

Bloomin' Brands Inc. Fourth-Quarter Report

1 Mins read
Despite a lower fourth-quarter profit, Bloomin’ Brands Inc. (BLMN) managed to exceed analyst estimates with its adjusted earnings thanks to a strong…

Leave a Reply

Your email address will not be published. Required fields are marked *

7 + 3 =